Thallion Pharmaceuticals Inc. is a biotech company that has developed a clinical program called Shigamabs. Shigamabs is a dual antibody product that is used for the treatment of Shiga toxin-producing E. coli ("STEC") bacterial infections. Thallion has completed four Phase I clinical trials evaluating the safety of Shigamabs®, and it has demonstrated that the antibodies are safe and well-tolerated when administered both individually and in combination. Thallion signed a €95 million development and license agreement with LFB, granting commercial rights to Shigamabs® for Europe, South America, and other territories of strategic interest to LFB, while Thallion retains rights for North America and the rest of the world. Thallion initiated a Phase II clinical trial in South America to evaluate Shigamabs® as a treatment for STEC infections.